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Abstract: The prevalence of heart failure with preserved ejection fraction (HFpEF) is constantly
increasing and no evidence-based pharmacological treatment option is available. While exercise
training (ET) improves diastolic function, its metabolic mechanisms in HFpEF are unclear. We assessed
the metabolic response to 12 weeks of ET in patients with HFpEF by performing a post hoc analysis of
the EX-DHF-P trial (ISRCTN86879094). Plasma concentrations of 188 endogenous metabolites were
measured in 44 ET and 20 usual care (UC) patients at baseline and 3-months follow-up. Metabolic
differences between ET and UC from baseline to follow-up were compared and differential responses
to ET were examined by random forest feature selection. ET prevented the increase of acetylornithine
and carnitine as well as the decrease of three glycerophospholipids. After ET, two opposite metabolic
response clusters were identified. Cluster belonging was associated with perceived well-being
at baseline and changes in low-density lipoprotein but not with cardiorespiratory, ventilatory or
echocardiographic parameters. These two ET-induced metabolic response patterns illustrate the
heterogeneity of the HFpEF patient population. Our results suggest that other biological parameters
might be helpful besides clinical variables to improve HFpEF patient stratification. Whether this
approach improves response prediction regarding ET and other treatments should be explored.
Keywords: exercise; heart failure with preserved ejection fraction; metabolomics
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1. Background
The prevalence of heart failure with preserved ejection fraction (HFpEF) is continuously
increasing [1]. Besides older age and female sex [2], several comorbidities, which include the
classical cardiovascular risk factors, like hypertension, obesity, diabetes mellitus and a sedentary
lifestyle, play a central pathophysiological role for disease development and progression [3,4]. In
contrast to heart failure with reduced ejection fraction, all clinical trials exploring pharmacological
treatment options for HFpEF have been negative or neutral [5,6].
Exercise training (ET), however, has been demonstrated to have cardioprotective effects in these
patients; specifically, an improvement in peak oxygen uptake, oxygen uptake at the anaerobic threshold,
six min walking distance and quality of life [7–12]. The metabolic mechanisms that contribute to these
improvements are not yet well understood. A possible explanation may be mitigation of the substantial
metabolic dysfunctions in HFpEF patients [13], since ET is well known to positively influence the
underlying metabolic comorbidities of HFpEF. Another putative mechanism could relate to influences
of ET on metabolic disturbances. In healthy humans, ET affects the purine, glucocorticoid, tryptophan
and androgen metabolism as well as glycolysis, gluconeogenesis, fatty acid metabolism, fatty acid
oxidation and the Krebs cycle [14]. Whether ET might also induce similar metabolic effects in patients
with HFpEF is currently unclear.
We used an exploratory approach to analyze the metabolic response to ET in participants of
the Exercise Training in Diastolic Heart Failure Pilot (EX-DHF-P) trial [9]. A targeted metabolomics
approach was used to identify differences between the ET and control group (usual care; UC). For
the ET group, we considered different outcome variables that have previously been described to be
positively changed by ET, such as parameters reflecting improvements in cardiopulmonary exercise
capacity and ventilatory efficiency (i.e., peak oxygen uptake (VO2peak) and minute ventilation/carbon
dioxide production (VE/VCO2) slope) as well as echocardiographic parameters characterizing reverse
atrial remodeling and improved left ventricular diastolic function (i.e., left atrial volume index (LAVI)
and ratio of early mitral inflow velocity (E) and peak early diastolic annular velocity (E/e’)).
2. Methods
2.1. Patient Population
This is a secondary analysis of Ex-DHF-P, a prospective, multicenter, randomized-controlled trial
on the effects of ET in HFpEF patients [9]. As described previously, of 71 screened patients, 67 were
included, and 64 were analyzed in the primary analysis. Supervised endurance and resistance training
in addition to UC was tested against UC only. The training program included 32 sessions over a time
period of three months. During weeks 1–4: aerobic endurance training (cycling, twice a week) of
increasing intensity and duration (20–40 min). The training intensity was individualized to a target
heart rate of 50–60% VO2peak assessed during baseline spiroergometry. After week four, the workload
was increased to a target heart rate of 70% of VO2peak (three times a week). At week five, resistance
training (bench press, leg press, leg curl, rowing machine, triceps dip, latissimus pull down) was
included twice a week. Resistance training was performed for 15 repetitions per exercise per session at
a work load corresponding to 60–65% of the one repetition maximum measured at the end of week four.
Echocardiography, including tissue Doppler parameters and calculation of left ventricular mass
index (LVMI) and LAVI, was performed according to current guidelines of the American Society of
Echocardiography [15]. A standard operating procedure was used to ensure comparability between
centers. Compared to UC, trial participants who received ET significantly improved their exercise
capacity and ventilatory efficiency (increase of VO2peak and VE/VCO2 slope), showed a reversed atrial
remodeling (reduction of LAVI) and an improved left ventricular diastolic function (decrease of E/e´).
Furthermore, ET was associated with an improvement of physical dimensions of quality of life [9].
Assessment methods for cardiopulmonary exercise capacity and ventilatory efficiency (i.e., VO2peak
and VE/VCO2 slope) and echocardiographic (i.e., E/e’ and LAVI) parameters of interest have been
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described elsewhere [9,16]. Self-perceived well-being was assessed using the SF-36 questionnaire and
the Patient Health Questionnaire (PHQ-9).
This secondary analysis only included study participants with available baseline and follow-up
plasma samples (UC: n = 20; ET: n = 44). EX-DHF-P was approved by the German Health Authorities
and the ethics committees of all participating recruiting centers. Further, all subjects gave written
informed consent before being included into the study.
2.2. Metabolomics
Ex-DHF-P utilized standard operating procedures for blood sampling. Fasted blood samples
from each patient were drawn on the same time of the day to avoid circadian variation and after a 20
min resting period in supine position. All samples were immediately centrifuged and stored at −80 ◦C.
Targeted metabolomics profiling of the plasma samples was performed using the AbsoluteIDQ p180
Kit (BIOCRATES LifeSciences AG, Innsbruck, Austria). A 10 µL aliquot of each plasma sample was
processed as recommended by the manufacturer. The fully automated assay combined flow injection
(FIA) and LC-MS/MS selective detection using MRM pairs and quantifies up to 188 metabolites from
5 different compound classes. Via FIA acyl carnitines, phospho- and sphingolipids were measured
in positive ionization mode and the sum of hexoses in negative ionization mode. With a LC-MS/MS
analytical method, under the use of an Agilent C18 column, amino acids and biogenic amines were
detected. MS analyses were performed on an AB SCIEX 5500 QTrap™ mass spectrometer (AB SCIEX,
Darmstadt, Germany) with electrospray ionization combined with an HPLC system (Agilent 1260
Infinity Binary LC, Santa Clara, CA, USA). Internal standards (isotope labelled) were partially integrated
in the kit plate for metabolite quantification.
2.3. Statistics
Several statistical approaches were combined to analyze how ET influenced the 188 metabolites.
First, general estimation equation (GEE) models were used in both groups to assess the association of
ET on the metabolites and to account for the repeating sampling character, i.e., paired observations.
Further, the group and time interaction was added to the model. We also performed several analyses
only in the ET group. Specifically, linear regression models were used with metabolites measured at
baseline as exposure and change in cardiorespiratory, ventilatory or echocardiographic parameters as
outcome. A p-value below 0.05 was considered significant and all analyses were implemented using
SAS 9.4 (SAS Institute Inc., Cary, NC, USA).
We used an unsupervised hierarchal clustering analysis (HCA) to identify differential metabolic
responses to ET. We calculated the changes in metabolite concentration between baseline and follow-up
and subsequently created residual variables from these values using linear regression models to regress
out the effect of age and sex. We then created Z-scores by subtracting the mean value of each residual
variable and divided by its standard deviation. Based on these variables we clustered the participants
using HCA with Euclidian distance and complete linkage. Number of clusters was determined by
calculation of silhouette coefficients. Variables important for cluster separation were selected using a
Boruta-feature selection approach. Briefly, Boruta uses random forest analyses for either regression or
classification purpose, thereby introducing so-called shadow variables, which are random variables
generated by shuffling from the original ones. The algorithm successively rejects unimportant features,
i.e., those with equal importance as the shadow variables (all features included are given in Table
S1). Statistical significance is derived from comparing the importance distribution of the original
attribute with its shadow after several permutations of the data set. We chose a p-value less than 0.01
as significant. HCA and feature selection analyses were implemented using R 3.3.2 (R Foundation for
statistical computing, Vienna, Austria).
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3. Results
The patient characteristics of the study sample are shown in Table 1. The two study groups did
not differ in any relevant baseline characteristic. Adherence to ET was on average 27.3 (±5.4) out of
32 possible training sessions.
Table 1. Patient characteristics.
Treatment Groups
Variable
All Subjects Exercise (EX) Control (CON) p-Value
n = 64 n = 44 n = 20
Female 36 (56%) 24 (55%) 12 (60%) 0.79
Age, years 65 ± 7 64 ± 8 65 ± 6 0.51
BMI, kg/m2 31 ± 5 31 ± 6 31 ± 4 0.96
Systolic blood pressure, mmHg 140 ± 19 140 ± 18 141 ± 20 0.97
Diastolic blood pressure, mmHg 82 ± 12 82 ± 10 82 ± 14 0.51
Hypertension 55 (86%) 38 (86%) 17 (85%) 1.00
Obesity 34 (53%) 22 (50%) 12 (60%) 0.59
Diabetes mellitus 9 (14%) 7 (16%) 2 (10%) 0.71
Hyperlipidemia 30 (47%) 20 (46%) 10 (50%) 0.79
Smoking status 0.65
Never smoker 28 (44%) 18 (41%) 10 (50%)
Ex-smoker 30 (47%) 21 (48%) 9 (45%)
Current smoker 6 (9%) 5 (11%) 1 (5%)
NHYA class 0.15
II 54 (84%) 35 (80%) 19 (95%)
III 10 (16%) 9 (20%) 1 (5%)
Echocardiography
baseline LVEF, % 67 ± 7 68 ± 7 67 ± 7 0.59
baseline E/e´ratio 13.0 ± 3.6 12.8 ± 3.2 13.5 ± 4.6 0.83
baseline LAVI, ml/m2 28.0 ± 7.9 27.9 ± 7.6 28.2 ± 8.8 0.88
change in E/e’ ratio −2.3 (−3.0–1.6) 0.6 (−0.6–1.8) <0.001
change in LAVI, ml/m2 −3.7 (−4.9–2.4) 0.3 (−0.7–1.4) <0.001
Spiroergometry
baseline peak VO2, ml/min/kg 16.3 ± 4.8 16.1 ± 4.9 16.7 ± 4.7 0.69
baseline VE/VCO2 slope 27.1 ± 2.9 27.5 ± 2.9 26.3 ± 2.9 0.27
change peak VO2, ml/min/kg 2.6 (1.8–3.4) −0.7 (−2.1–0.7) <0.001
change VE/VCO2 slope 0.02 (−5.0 – 5.0) 0.6 (−4.0 – 4.0) 0.08
Medication
ACE inhibitor/AT1 receptor
antagonist 42 (66%) 31 (70%) 11 (55%) 0.26
Beta-blocker 32 (50%) 20 (45%) 12 (60%) 0.42
Diuretics 29 (45%) 21 (48%) 8 (40%) 0.6
Statins 17 (27%) 12 (27%) 5 (25%) 0.59
Laboratory parameters
LDL-C, mg/dl 137 ± 32 136 ± 31 134 ± 34 0.79
HDL, mg/dl 61 ± 21 62 ± 23 58 ± 16 0.698
Hb, g/dl 14.3 ± 1.2 14.5 ± 1.2 13.8 ± 1.2 0.027
eGFR, ml/min 85 ± 14 85 ± 15 86 ± 11 0.517
SF-36 (physical) 43 ± 7 43 ± 9 44 ± 10 0.439
SF-36 (general health) 58 ± 18 56 ± 18 59 ± 18 0.276
SF-36 (vitality) 52 ± 20 51 ± 21 54 ± 17 0.149
Values are n, frequency (%) or mean ± SD. ACE, angiotensin-converting enzyme; AT, angiotensin; BMI, body
mass index; SF-36, Short Form-36 health survey; LAVI, left atrial volume index; LDL-C, low-density lipoprotein
cholesterol; LV, left ventricular; LVEF, LV ejection fraction; NYHA, New York Heart Association.
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3.1. Metabolic Response to Exercise Training
A total of ten metabolites showed a significant difference when the progression from baseline
to follow-up was compared in ET and UC (Table 2). This was exemplified by the significant or near
significant time*group interactions, which indicate an opposite directionality in change of metabolite
concentration. Glutamine modestly increased and three sphingolipids (SM C18:0, SM C24:0 and SM
(OH) C16:1) slightly decreased in ET but remained constant in UC. Acetylornithine and carnitine
significantly increased, and three glycerophospholipids (PC aa C28:1, PC aa C34:2, PC aa C36:2)
moderately declined in UC but remained constant in ET. PC ae C44:4 had a borderline significant
interaction (p = 0.06).
3.2. Metabolic Response to Exercise Training Depending on Different Outcome Parameters
The baseline concentrations of 42, 36, 12 and 9 metabolites were associated with changes in
VO2peak, VE/VCO2, E/e’ and LAVI due to ET, respectively (Figure 1; Tables S2–S5). Interestingly, very
little overlap existed between these outcome parameters, which suggests involvement of different
underlying metabolic pathways. Specifically, the baseline concentrations of tryptophan, spermidine,
35 glycerophospholipids and five sphingolipids were related with improvements in VO2peak. Leucine,
asymmetric dimethylarginine, taurine, H1 (sum of hexoses) and 29 glycerophospholipids were
associated with changes in VE/VCO2 slope. Improvement of LV diastolic dysfunction assessed by
reductions in E/e’ was associated with the baseline concentrations of glycine, serine, spermine, two
sphingolipids (SM C18:0 and SM C22:3), four glycerophospholipids (PC aa C38:5, PC aa C40:5, PC
ae C30:1 and PC ae C44:5), two acetylcarnitines (propionylcarnitine and valerylcarninitine) and H1.
Reductions in LAVI were associated with tetradecadienylcarnitine, leucine, serotonin, spermidine and
five glycerosphospholipids (PC aa C36:2, PC aa C38:4, PC ae C34:2, PC ae C34:3 and PC ae C36:3) at
baseline (Figure S3).
With regards to the low overlap between the different outcome parameters, spermidine
concentration at baseline was related to both higher VO2peak and lower LAVI and a total of twelve
glycerophospholipids were associated with improvements in both VO2peak and VE/VCO2 slope.
Additionally, H1 (sum of the hexoses) concentration showed significant relations with both lower E/e’
and VE/VCO2 slope, while serotonin was associated with LAVI and VE/VCO2 slope.
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Table 2. Metabolic changes from baseline to follow-up.
Exercise Control p-Value
Class Metabolite Baseline Follow-Up Baseline Follow-Up Training Control Interaction
Biogenic Amines Acetylornithine
(Ac_Orn)
0.793 0.959 0.913 0.843
0.88 0.01 0.03(0.499, 1.615) (0.558, 1.560) (0.789, 2.290) (0.578, 1.388)
Acylcarnitines Carnitine (C0) 38.32 37.71 38 43.16 0.83 <.01 0.05(32.89, 42.91) (32.64, 43.79) (35.02, 43.05) (38.01, 47.38)
Glycerophospholipids PC aa C28:1 3.51 3.46 3.21 3.45 0.64 0.05 0.05
(2.71, 4.37) (2.75, 4.39) (2.68, 3.48) (3.03, 4.15)
PC aa C34:2 320.56 315.63 295.54 313.66 0.35 0.01 0.05
(289.39, 359.66) (278.61, 365.21) (271.55, 323.82) (294.72, 341.21)
PC aa C36:2 197.75 193.08 177.82 194 0.61 0.02 0.03
(166.88, 219.16) (155.07, 228.27) (157.52, 202.85) (184.85, 212.88)
PC ae C44:4
0.29 0.29 0.29 0.31
0.24 0.15 0.06(0.25, 0.33) (0.24, 0.32) (0.27, 0.31) (0.28, 0.34)
sphingolipids SM C18:0 17.59 17.22 16.4 16.64 0.04 0.32 0.04
(14.73, 21.29) (14.02, 20.03) (14.02, 18.65) (15.17, 19.31)
SM C24:0 12.25 11.4 11.23 11.05 0.02 0.51 0.08
(10.32, 13.61) (9.13, 13.51) (10.22, 12.41) (9.87, 13.88)
SM (OH) C16:1 2.66 2.64 2.4 2.69 0.08 0.27 0.07
(2.09, 3.28) (2.02, 3.24) (2.16, 2.75) (2.01, 2.98)
Amino Acid Glutamine (Gln)
518.12 550.89 512.72 553.8
<.01 0.89 0.09(465.98, 572.04) (519.69, 612.37) (480.11, 611.33) (448.19, 597.87)
All units are given as µmol/L (median and 25th as well as 75th percentile).
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Figure 1. Association of baseline metabolome with changes in outcome parameters after exercise
training. The Venn diagram displays the total number of metabolites associated with the four outcome
parameters, VO2peak, VE/VCO2 slope, ratio of transmitral Doppler early filling velocity to tissue
Doppler early diastolic mitral annular velocity (E/e’) and left atrial volume index (LAVI). The number
in the sections where two or more ellipses overlap provide the total number of metabolites associated
with two or more outcomes.
3.3. Metabolic Clustering due to Exercise Training in HFpEF Patients
A non-supervised clustering was used to identify subgroups of patients with similar metabolic
response patterns to 12 weeks of ET. A total of 39 metabolites differed strongly between the two
identified clusters with an opposite response (i.e. upregulation in cluster 1 and downregulation in
cluster 2) to ET. The metabolites identified by Boruta feature selection included spermine, lyso PC a
C18:0, lyso PC a C18:1, 29 glycerophospholipids and seven sphingolipids (SM (OH) C14:1, SM (OH)
C16:2, SM (OH) C 22:1, SM (OH) C22:2, SM C16:0, SM C18:0 and SM C24:0) (Figure 2). The two groups
included nine (cluster 1) and 35 subjects (cluster 2), respectively. The patients were very similar with
regards to their clinical baseline characteristics and adherence to ET. However, cluster belonging was
determined by self-perceived well-being and change in plasma LDL cholesterol from BL to FU as well
as BL concentrations of only two out of the 39 metabolites differing between groups (i.e., lyso PC a
C:18 and PC ae C38:6) (Figure S1).
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Figure 2. Metabolic response to exercise training in heart failure with preserved ejection fraction
(HFpEF) patients. The top heatmap displays the results of the non-supervised clustering by similarity
in metabolite concentration change from baseline to follow-up in the rows. Study participants were
clustered according to similarity in response to exercise training (ET) displayed by the dendogram
located on the top of the heatmap. The two smaller heatmaps on the bottom show the results of the
random forest analysis, which included baseline parameters (self-perceived well-being based on the
SF-36 questionnaire) and change in low-density lipoprotein (LDL) from baseline to follow-up as well as
two metabolites (in bold lettering: lyso PC a C:18 and PC ae C38:6), which significantly influenced
cluster belonging. BMI—body mass index, Hb—hemoglobin, VLEDD—left ventricular end-diastolic
diameter, SF-36—short form survey 36, GH—general health, PG—psychological health, PCS—physical
component score, PHQ-9—Patient Health Questionnaire 9, LDL—low density lipoprotein cholesterol.
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4. Discussion
This study assessed the metabolic response to structured and supervised ET in HFpEF patients
and had three main findings. First, we found that some metabolites changed differently from
baseline to follow-up when ET and UC were compared. Specifically, ET increased glutamine and
decreased sphingolipid concentrations. Furthermore, acetylornithine and carnitine increased and
three glycerophospholipids (PC aa C28:1, PC aa C34:2 and PC aa C36:2) decreased in UC while these
alterations were prevented by ET. Second, we report an outcome-specific metabolic signature after
ET with very little overlap between cardiorespiratory, ventilatory and echocardiographic parameters.
This suggests that in our small sample ET may have induced different metabolic responses, each
related to beneficial changes that have previously been shown to contribute to positive clinical effects
of ET in HFpEF, like improvement in exercise capacity or reversed cardiac remodeling [9]. Third, we
identified two separate metabolic signatures among participants in the ET group. Importantly, in this
specific group of HFpEF patients the only parameters that were associated with cluster belonging
were self-perceived well-being at baseline, change in plasma LDL from baseline to follow-up as well
as baseline concentration of two metabolites (lyso PC a C:18 and PC ae C38:6) (central illustration).
These results may underscore the possibility of a necessary stratification of patients with HFpEF based
on yet underappreciated parameters like self-perceived well-being. Nonetheless, the identification
of these two response signatures suggests that even though the subjects who performed ET on
average significantly improved their cardiorespiratory exercise capacity and left ventricular diastolic
dysfunction, the biological and metabolic signaling mechanisms may have not been the same but
rather were dependent on individual patient characteristics.
The observed response to ET in HFpEF patients is in agreement with previous studies. Specifically,
acetylcarnitines and carnitine are changed by exercise and during the progression of heart failure [17,18].
Mitochondrial fatty acid oxidation supplies 60 to 70% of the ATP required for appropriate muscle
contraction in the healthy heart [19]. Since fatty acids are bound to lipoproteins or albumins in
non-esterified form in the blood, acetyl-CoA synthases are required for the conversion to fatty acid
acetyl-CoA esters. The carnitine shuttle systems supplies the transport of these esters into the
mitochondria for free fatty acid oxidation. Specifically, carnitine binds to the fatty acetyl-CoA to
form fatty acetyl-carnitine [20]. Carnitine regulation is disturbed in chronic heart failure [21]. In our
analysis carnitine increased in UC and remained constant in ET. Therefore, our results suggest that
one mechanism by which exercise improves cardiac function in HFpEF patients may be an improved
energy homeostasis by influencing carnitine availability.
Spermidine, a polyamine which induces autophagy, reduces the cardiometabolic risk in humans
and is related with increased longevity in mice and rats [22]. Our results show that the baseline
concentrations of spermidine and its derivative spermine are related to improvements in exercise
capacity (i.e., VO2peak) and cardiac remodeling (i.e., LAVI and E/e’) (Figure S2). Autophagy is
a cellular quality control mechanism essential for appropriate protein folding and maintenance
of cell function. Constitutive autophagy in healthy hearts is a homeostatic mechanism for the
preservation of cardiomyocyte size, global cardiac structure and function [23]. During heart failure
autophagy is upregulated to protect the cell from hemodynamic stress [23]. In addition, inhibiting
autophagy by cardiomyocyte specific knockout of the autophagy-related 5 gene induces age-related
cardiomyopathy [24]. Interestingly, not all subjects responded equally to ET with regards to spermine.
Specifically, spermine concentration increased in subjects belonging to the metabolic cluster 1 but
decreased in those in cluster 2. Currently, we cannot explain this observation and future studies need
to explore the relation between exercise, autophagy and spermine signaling.
While in our small sample, ET was beneficial for all HFpEF patients and the metabolic responses
were heterogeneous. Two distinct metabolic signatures were identified in the ET group. A higher
abundance of the significant metabolites was found in cluster 1, while they were lower in cluster 2. We
used a random forest analysis with more than 300 features, including echocardiographic parameters,
adherence to exercise intervention, blood lipids and medications (for a complete list see Table S1),
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to identify subject characteristics, which were related to cluster belonging. In these 44 patients with
HFpEF self-perceived well-being, change in plasma LDL and baseline concentration of only two
glycerophospholipids (lyso PC a C 18:0 and PC ae C38:6) were the only significant predictors of
cluster belonging.
This peculiar finding is of interest as current HFpEF stratification systems generally rely on clinical
patient characteristics [2]. Similar results were also reported for the DIAST-CHF trial in which impaired
self-perceived physical quality of life was more strongly associated with neurohumoral activation
than with echocardiographic parameters [25]. Nonetheless, considering that the subjects voluntarily
entered a trial which explored the effect of ET, one could assume that the participants had a sufficient
level of self-perceived well-being which allowed them to exercise three times per week. In addition,
due to the supervised nature of EX-DHF-P, the adherence to ET in this trial was very good. Future
studies should further explore the influence of self-perceived well-being on the metabolic signaling
mechanisms of exercise.
Even though our analysis is the first to comprehensively characterize the metabolic response to ET
in patients with HFpEF of a controlled, randomized and prospective trial, some limitations have to be
recognized when interpreting the findings. We acknowledge that our analysis is of exploratory nature
and that we only analyzed a relatively small number of patients, although they were phenotypically
very well characterized. We also recognize that the clusters identified may simply be a random finding
due to the small sample size. Hence, much larger trials are required to validate our results. Another
limitation is that our analyses is based on a targeted metabolomics approach by utilizing a commercially
available platform with a set of 188 metabolites. Thus, not yet known metabolites of potential interest
have not been addressed by our methodology. Nonetheless, this platform allows the comparison of our
findings with previous research in the field of exercise metabolomics. In addition, our results confirm
previous findings and provide a basis for future experimental studies, which need to investigate the
relationships between the metabolites identified in this investigation and ET-induced cardiorespiratory,
ventilatory and echocardiographic outcomes in HFpEF patients.
In summary, our preliminary findings based on a small yet well characterized group of patients
with HFpEF support the previously-established notion of carnitine shuttle system dysregulation in
heart failure and suggest that exercise may improve cardiac energy homeostasis in HFpEF through
this pathway. Further, our exploratory analysis identified that different signaling mechanisms may
be responsible for cardiorespiratory, ventilatory and echocardiographic adaptations due to ET. This
is important for the design of future exercise trials as it reiterates the importance of appreciating the
systemic effects of exercise even in patients with HFpEF, which activates a multitude of signaling
mechanisms. Future trials need to validate our findings in larger HFpEF patient populations to
assess whether HFpEF patients should be stratified not just by already known clinical parameters,
like comorbidities, but also currently unknown parameters which might influence the biological and
metabolic response to ET.
5. Clinical Relevance
HFpEF is a syndrome characterized by a large heterogeneity not only with respect to underlying
risk factors and comorbidities but also regarding the individual metabolic profiles of affected patients.
In this exploratory post-hoc analysis exercise training improved the energy metabolism in HFpEF, and
exercise-induced improvements of exercise and ventilatory capacity as well as ventricular dysfunction
were associated with several of these metabolic changes. In addition, we identified heterogeneous
metabolic responses to the same exercise training in HFpEF patients independent of improvements in
cardiorespiratory, ventilatory and echocardiographic parameters.
In the future, metabolic and other biological profiles might be used besides clinical variables
for a better stratification of HFpEF patients. This knowledge could be helpful for a personalized
prescription and response prediction regarding exercise training programs and other upcoming
treatments, including pharmacological therapies.
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Abbreviations
HFpEF heart failure with preserved ejection fraction
ET exercise training
EX-DHF-P exercise training in diastolic heart failure-pilot trial
UC usual care group
LVMI left ventricular mass index
LAVI left atrial volume index
VO2peak peak oxygen consumption
VE/VCO2 slope minute ventilation/carbon dioxide production slope
E/e’
ratio of transmitral Doppler early filling velocity to tissue Doppler
early diastolic mitral annular velocity
FIA flow injection analysis
GEE generalized estimating equation
LDL low-density lipoprotein
BL baseline
FU follow-up
HCA hierarchical clustering analysis
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